Mannywill submit to as many random urine tests requested

The contributions deal with topics related to understandingand predicting the chemistry and technology of processing, fabrication,structure, properties and history of glass. The collection is divided into ten thematic sections: Glass structure Thermodynamics, rheology, and the glass transition Physical properties of glass Optical, electrical and magnetic properties of glass Bioglass and chemical durability Nucleation, crystallization and sintering Glass melting Glass forming, and glass production Refractories; and Ecology and waste materials.Key Topics Covered: Preface Committees Referees Sales and Service Representative Sponsors Section 1: Glass Structure Author Index Keyword IndexFor more information visit http:// WoodSenior Fax from USA: 646-607-1907Fax from rest of the world: 353-1-481-1716 Copyright Business Wire 2009. Top Rank Promotions wasted no time releasing a statement in response to Mayweather and Golden Boy Promotions regarding Manny Pacquiao's unwillingness to submit to a blood test in the days leading up to their bout.Contrary to many reports that surfaced yesterday afternoon, it isn't the blood test itself that Team Pacquiao has an issue with, butmore-so the specific agency that will be handling the tests.Bob Arum, founder of Top Rank stated, “Let’s be very clear on the real issues we differ on. It’s not about being tested. Manny is onboard with that since it’ssuch a major concern of Floyd Mayweather, Jr. It’s about who does the testing and thescheduling of the procedures. Mannywill submit to as many random urine tests requested. Regarding the blood tests, he willsubject himself to three tests; one given in January during the week the fightis formally announced, one thirty days from the fight, no later than February13, and the final one immediately following the fight, in Manny’s locker room. "The major issue related to thetesting rests with which independent agency will administer these tests. The United States Anti Doping Agency(USADA) cannot do it because they will not amend its procedures to accommodatethe blood testing schedule we have outlined. USADA, under its guidelines, would havethe right to administer random blood tests as many times as they want up toweigh-in day and that is ludicrous."To further disprove the notion that Manny is weary of submitting to a blood test, Arum offered up a solution in an attempt to make this "super fight" the reality it appeared to be just a couple of days ago.“Oursuggestion is to utilize any of the independent agencies that work with theNational Football League, the National Basketball Association, or Major LeagueBaseball, since they administer drug testing for their professionalathletes.”While Top Rank, on behalf of Pacquiao, has made it clear that they are willing to submit blood tests up to 30 days prior to the bout (as well as immediately afterwards), some experts, such as New York based athletic physician, Dr. And the urine testing is sufficient that youwon't miss anything, especially with performance-enhancing drugs. So, yes, Ibelieve that the urine testing is more than sufficient for boxing.

If you'reusing steroids, it's going to come up for sure in urine. There's no way it'sgoing to get through the liver and the kidney without being detected."Never one to shy away from a war of words, Arum would conclude that, "IfMayweather Promotions and Golden Boy Promotions are sincere in creating 'a level playing field,' as they stated in their release, ourrecommendations should put their minds at ease. If not, one has to wonder if theirmotives are more about leveling the fight.”It looks as if Top Rank and Team Pacquiao are willing to do what it takes to make this fight a reality, the ball in back in the court of Floyd Mayweather and Golden Boy Promotions, as they represent him for this fight.Expect more on the story as it develops.Questions and comments can be sent to . BERKELEY HEIGHTS, N.J.(Business Wire)Genta Incorporated (OTCBB: GNTA) announced today that the Company has receivednotice from the U.S. Food and Drug Administration (FDA) that tesetaxel, thelatest addition to Gentas oncology product portfolio, has been granteddesignation as an "Orphan Drug" for treatment of patients with advanced gastriccancer. Orphan drug status provides for a period of marketing exclusivity,certain tax benefits, and an exemption from certain fees upon submission of aNew Drug Application. As a late Phase 2 agent, the Company believes tesetaxel isthe leading oral taxane currently in clinical development.

In the completed Phase 2 study, 35 patients with advanced gastric cancer weretreated with tesetaxel at doses ranging from 27 to 35 mg/m2 once every threeweeks. All patients had received extensive prior treatment, having failed acombination regimen that included cisplatin plus 5-fluorouracil or Xeloda, andall but 2 patients had received a third chemotherapy drug with this regimen.Final intent-to-treat analysis, including all patients enrolled in the study,showed that 5 patients achieved a partial response, 2 patients achieved apartial response unconfirmed by CT scan, and 14 patients achieved stabledisease, for an overall major response rate of 20 and a disease-control rate of60. The most serious adverse reaction was Grade 3-4 neutropenia, which occurredin 57 of patients. Five patients died on study from differing causes that includedintestinal perforation, pneumonia, hepatic failure, hemorrhagic shock, and rapiddisease progression. One patient withdrew before receiving the first treatmentdose. "These response data for tesetaxel in a critically ill patient population showclinical activity at levels that are at least comparable to studies with othertaxanes," said Dr Raymond P.

Warrell, Jr., Gentas Chief Executive Officer."Based on these data, we have consulted extensively with international expertsand will be defining a global registration path for tesetaxel as a 2nd-linetreatment for patients with advanced gastric cancer. FDA designation as anOrphan Drug provides important assistance in the clinical development process." About TesetaxelTesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the sameclass of drugs as paclitaxel and docetaxel. However, both prototype agentssuffer from serious safety issues, particularly hypersensitivity reactionsrelated to intravenous infusions that are occasionally fatal and that requirecareful premedication and observation. Other prominent side-effects of this drugclass include myelosuppression (low blood counts) and peripheral neuropathy(disabling nerve damage). With administration as an oral capsule, tesetaxel was developed to maintain thehigh antitumor activity of the taxane drug class while eliminating infusionreactions, reducing neuropathy, and increasing patient convenience.